Phospho-specific antibodies’ typical purpose is to enable researchers to detect changes in proteins. They will exclusively bind to the amino acid sequence on a protein that has been phosphorylated (which is both a physical & chemical change) and do not bind to the same amino acid sequence on said protein if it lacks said phosphorylation. This aids in being able to clearly see and understand the data produced from this particular protein modification.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human skeletal muscle tissue, using AMPK beta1 (Phospho-Ser181) antibody. Western blot analysis of extracts from COS7 cells treated with PMA (125ng/ml, 30mins), using AMPK beta1 (Phospho-Ser181) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from K562 cells, using Met (phospho-Tyr1349) antibody. Western blot analysis of extracts from HepG2 cells, using Met (phospho-Tyr1349) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatogramphy using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human colon carcinoma tissue using PAK2 (Phospho-Ser20) antibody. Western blot analysis of extracts from 293 cells, treated with Sorbitol (0.4M, 30mins), using PAK2 (Phospho-Ser20) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IF (Immunofluorescence) (P-peptide-+ Immunofluorescence analysis of HepG2 cells, using c-Met (Phospho-Tyr1003) antibody.)
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human colon carcinoma tissue using c-Met (Phospho-Tyr1003) antibody. Western blot analysis of extracts from HepG2 cells, using c-Met (Phospho-Tyr1003) antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human brain tissue using Ephrin B1/B2 (Phospho-Tyr329) antibody. Ephrin B1/B2 (Phospho-Tyr329) antibody reacts with epitope-specific phosphopeptide and corresponding non-phosphopeptide. The absorbance readings at 450 nM are shown in the ELISA figure.)
Affinity-purified fromrabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue using PDCD4 (Phospho-Ser457) antibody. Western blot analysis of extracts from 293 cells, treated with serum (20%, 15mins), using PDCD4 (Phospho-Ser457) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human brain tissue using PTP1B (Phospho-Ser50) antibody. Western blot analysis of extracts from COS7 cells, treated with UV (30mins), using PTP1B (Phospho-Ser50) antibody.)
Affinity-purified fromrabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue using ERK3 (Phospho-Ser189) antibody. Western blot analysis of extracts from mouse brain, using ERK3 (Phospho-Ser189) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human lung carcinoma tissue using Ku70 (Phospho-Ser5) antibody. Western blot analysis of extracts from HeLa cells, using Ku70 (Phospho-Ser5) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Pricing
WB (Western Blot) (Western blot analysis of extracts from RAW264.7 cells, using TISB (Phospho-Ser92) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from 293 cells treated with TNF-alpha (20ng/ml, 30mins), using NF-kappaB p65 (phospho-Ser311) antibody (Line 1 and 2).)
IHC (Immunohistochemistry) (P-peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using NF-kappaB p65 (phospho-Ser311) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extract from A431 ce lls, untreated or treated with EGF (200ng/ml, 5min), using Bcr (Ab-177) antibody and Bcr(phospho-Tyr177) antibody.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human tonsil tumor tissue, using Bcr (phospho-Tyr177) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from NIH/3T3 cells treated with using Serum. Left: Using FOXO3A (phospho-Ser253) antibody. Right: Using the same antibody preincubated with synthesized peptide.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using FOXO3A (phospho-Ser253) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatogramphy using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from CV-1 cells treated with forsklin. Left: Using LKB1 (phospho-Ser428) antibody. Right: Using the same antibody preincubated with synthesized peptide.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using LKB1 (phospho-Ser428) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatogramphy using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from NIH-3T3 cells, using p44/42 MAP Kinase (Ab-204) antibody and p44/42 MAP Kinase (phospho-Tyr204) antibody.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue, using p44/42 MAP Kinase (phospho-Tyr204) antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from HeLa cells using STAT3 (phospho-Ser727) antibody.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using STAT3 (phospho-Ser727) antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from COLO205 cells (Lane 1 and 2) and K562 cells (Lane 3), using CDC2 (phospho-Thr161) antibody.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue, using CDC2 (phospho-Thr161) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatogramphy using non-phosphopeptide corresponding to the phosphorrylation site.
WB (Western Blot) (Western blot analysis of extract from A431 cells untreated or treated with EGF (200ng/ml, 5min), using EGFR (Ab-1197) antibody and EGFR (phospho-Tyr1197) antibody.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue, using EGFR (phospho-Tyr1197) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatogramphy using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from MDA-MB-435 cells, untreated or EGF-treated (200 ng/ml, 30min), using 4E-BP1 (Ab-36) antibody and 4E-BP1 (phospho-Thr36) antibody.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using FKHRL1 (phospho-Ser253) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatogramphy using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis using Akt2 (Ab-474) antibody and Akt2 (phospho-Ser474) antibody.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human lung carcinoma tissue using Akt2 (phospho-Ser474) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatogramphy using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from 293 cells using JunD (phospho-Ser255) antibody.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using JunD (phospho-Ser255) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human brain tissue using SAPK/JNK (Phospho-Tyr185) antibody. Western blot analysis of extracts from HepG2 cells, treated with nocodazole (1ug/ml, 16hours), using SAPK/JNK (Phospho-Tyr185) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human placenta tissue using CDC37 (Phospho-Ser13) antibody. Western blot analysis of extracts from NIH/3T3 cells, using CDC37 (Phospho-Ser13) antibody.)
Affinity-purified fromrabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (P-peptide-+ Western blot analysis of extracts from K562 cells, using Epo-R (Phospho-Tyr368) antibody. Immunofluorescence analysis of HepG2 cells, using Epo-R (Phospho-Tyr368) antibody.)
Affinity-purified fromrabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Pricing
IHC (Immunohistochemistry) (P-peptide-+ Immunohistochemistry analysis of paraffin-embedded human heart tissue using NFAT2 (Phospho-Ser294) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatogramphy using non-phosphopeptide corresponding to the phosphorylation site.
IF (Immunofluorescence) (Immunofluorescent analysis of AKT (pY315) staining in A549 cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of AKT (pY315) staining in human brain formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of AKT (pY315) expression in HeLa (A), A549 (B), LOVO (C), HepG2 (D), NIH3T3 (E) whole cell lysates.)
IHC (Immunohiostchemistry) (PEK/PERK (Phospho-Thr981) antibody reacts with epitope-specific phosphopeptide and corresponding non-phosphopeptide. The absorbance readings at 450 nM are shown in the ELISA figure.)
Application Data (Immunohistochemistry analysis of paraffin-embedded human prostate carcinoma tissue using PEK/PERK (Phospho-Thr981) antibody.)
Affinity-purified fromrabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from Jurkat cells, treated with EGF (200ng/ml, 15mins), using GR (Phospho-Ser226) antibody (#A0432).)
IHC (Immunohistochemistry) (P-peptide-+ Immunohistochemical analysis of paraffin-embedded human lung carcinoma tissue using GR (Phospho-Ser226) antibody (#A0432).)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IF (Immunofluorescence) (P-peptide-+ Immunofluorescence analysis of HeLa cells, using Calnexin (Phospho-Ser583) antibody.)
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue using Calnexin (Phospho-Ser583) antibody. Western blot analysis of extracts from HeLa cells, treated with EGF (200ng/ml, 30mins), using Calnexin (Phospho-Ser583) antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue using MYT1 (Phospho-Ser83) antibody. MYT1 (Phospho-Ser83) antibody reacts with epitope-specific phosphopeptide and corresponding non-phosphopeptide. The absorbance readings at 450 nM are shown in the ELISA figure.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human brain tissue using CNOT2 (Phospho-Ser101) antibody. CNOT2 (Phospho-Ser101) antibody reacts with epitope-specific phosphopeptide and corresponding non-phosphopeptide. The absorbance readings at 450 nM are shown in the ELISA figure.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Application Data (53BP1 (Phospho-Ser25) antibody reacts with epitope-specific phosphopeptide and corresponding non-phosphopeptide. The absorbance readings at 450 nM are shown in the ELISA figure.)
IHC (Immunohiostchemistry) (P-peptide-+ Immunohistochemistry analysis of paraffin-embedded human colon carcinoma tissue using 53BP1 (Phospho-Ser25) antibody. Immunofluorescence analysis of NIH/3T3 cells, using 53BP1 (Phospho-Ser25) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody againstnon-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from COS7 cells treated with EGF (200ng/ml, 30mins), using PLCG1 (phospho-Tyr771) antibody.)
IHC (Immunohistochemistry) (P-peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using PLCG1 (phospho-Tyr771) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Pricing
WB (Western Blot) (Western blot analysis of extracts from Mouse brain cells, using GRIN2B (Phospho-Ser1303) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human heart tissue using Bloom Syndrome Protein (Phospho-Thr99) antibody. Western blot analysis of extracts from HepG2 cells, using Bloom Syndrome Protein (Phospho-Thr99) antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Affinity-purified fromrabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from Jurkat cells, using Chk2 (Phospho-Thr387) Antibody (#A0414).)
IHC (Immunohistochemistry) (P-peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Chk2 (Phospho-Thr387) Antibody (#A0414).)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from HuvEc cells, treated with Serum (20%, 30mins), using Histone H3 (Phospho-Thr3) antibody (#A0434).)
IHC (Immunohistochemistry) (P-peptide-+ Immunohistochemical analysis of paraffin-embedded human lung carcinoma tissue using Histone H3 (Phospho-Thr3) antibody (#A0434).)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IF (Immunofluorescence) (TNF-a +- Immunofluorescence analysis of HeLa cells, treated with TNF-a (20nM, 15mins), using HSP90B (phospho-Ser254) antibody (#11313).)
WB (Western Blot) (Western blot analysis of extracts from Hela cells treated with TNF-alpha (20ng/ml, 30mins), using HSP90B (phospho-Ser254) antibody.)
IHC (Immunohistochemistry) (P-peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using HSP90B (phospho-Ser254) antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Pricing
WB (Western Blot) (Western blot analysis of extracts from A549 cells, treated with dexamethason (10nM, 1hour), using GR (Phospho-Ser203) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue using PKC delta (Phospho-Tyr313) antibody. Western blot analysis of extracts from HuvEc cells, treated with TNF-a (20ng/ml, 30mins), using PKC delta (Phospho-Tyr313) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from 293 cells using Src (Ab-529) antibody (Line1 and 2) and Src (phospho-Tyr529) antibody (Line 3 and 4).)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Src (phospho-Tyr529) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IF (Immunofluorescence) (PMA +- Immunofluorescence analysis of HeLa cells, treated with PMA (125ng/ml, 30mins), using POLR2A (phospho-Ser1619) antibody.)
WB (Western Blot) (Western blot analysis of extracts from COS7 cells treated with EGF (200ng/ml, 30mins), using POLR2A (phospho-Ser1619) antibody.)
IHC (Immunohistochemistry) (P-peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using POLR2A (phospho-Ser1619) antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IF (Immunofluorescence) (P-peptide-+ Immunofluorescence analysis of HeLa cells, using ETS1 (Phospho-Thr38) antibody.)
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue using ETS1 (Phospho-Thr38) antibody. Western blot analysis of extracts from HeLa cells, treated with Serum (20%, 15mins), using ETS1 (Phospho-Thr38) antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from RAW264.7 cells, treated with UV (15mins), using 14-3-3 beta/zeta (Phospho-Ser184/186) antibody. 14-3-3 beta/zeta (Phospho-Ser184/186) antibody reacts with epitope-specific phosphopeptide and corresponding non-phosphopeptide. The absorbance readings at 450 nM are shown in the ELISA figure.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human colon carcinoma tissue using WAVE1 (Phospho-Tyr125) antibody. Western blot analysis of extracts from NIH/3T3 cells, treated with Insulin (0.01U/ml, 15mins), using WAVE1 (Phospho-Tyr125) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue using PKR (Phospho-Thr258) antibody. Western blot analysis of extracts from Jurkat cells, treated with starved (24hours), using PKR (Phospho-Thr258) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human brain tissue using Trk A (Phospho-Tyr701) antibody. Western blot analysis of extracts from mouse brain cells, using Trk A (Phospho-Tyr701) antibody.)
Affinity-purified fromrabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Pricing
What Are Phospho Antibodies?
Protein phosphorylation is a process where a phosphate group is added to certain amino acid residues of a protein – usually serine (S), threonine (T), or tyrosine (Y) - by enzymes called kinases. This process is integral in controlling cellular signaling, cellular growth, and other biological functions.
Our catalog includes a wide range of phospho-specific antibodies that can accurately detect this important marker. They perform strongly in widely-used laboratory applications such as Western blot, flow cytometry, immunohistochemistry, and immunofluorescence microscopy. We value your trust in us and are committed to providing top-quality products and services. All of our antibodies are guaranteed to work for the applications and species indicated on our website & associated product pages.
What Are The Key Applications of Phospho Antibodies?
1. Western Blotting
One of the first steps a researcher can take in utilizing these phospho-specific antibodies, is to check if the antibody works using a technique referred to as “Western blot”. For those unfamiliar, Western Blot aids in showing whether the protein that the antibody recognizes is appearing at the correct/expected size. These phospho-specific antibodies should also be able to detect changes in the target protein’s phosphorylation (on/off state) when cells are stimulated in certain ways.
2. Staining of Fixed Cells (Immunocytochemistry)
Another routine use of these phospho-specific antibodies, is to test if the antibody is able to demonstrate similar performance when used on fixed cells (intact cells that have been preserved) as it did in the Western blot tests. It is an important aspect in many cases to confirm that the antibody works in actual intact cell samples. Ideally, the method used for cellular fixation should be the same as what is used in pathology labs (like using 10% formalin). To check if the antibody works well in tissue sections (FFPE), researchers will often test it on fixed cells that are processed similar to tissue samples.
3. Specificity Tests Using Peptides
In order to make sure that the antibody is only binding to the right target:
Laboratory technicians will mix the antibody with phospho-peptides (short segments of the protein containing the phosphate group modification).
If the antibody signal disappears, it is confirmation that it is binding to the correct phosphorylated location.
A more robust test is to use both the phosphorylated and non-phosphorylated (dephosphorylated) versions of the protein. The antibody should react only with the phosphorylated one.
Another method sometimes utilized is to treat the sample with an enzyme, such as alkaline phosphatase, that specifically removes phosphate groups. If the antibody signal disappears after this, it also confirms specificity.
4. Genetic Confirmation
As a final step, scientists can genetically manipulate the nucleotide sequence and alter the target protein by removing the exact site where phosphorylation happens. If the antibody no longer appears to detect the modified protein, it is strong evidence supporting the antibody being specific for that phosphorylated site.
Why Buy Phospho Antibodies Through Us?
The production laboratory adheres to strict and consistent protocols prior to releasing any of these phospho-specific antibodies:
Standard methods and proper controls in all tests to ensure high quality.
These antibodies are tested and validated in different cell types and species.
High quality control criterion to ensure each batch is consistent, so you will obtain reliable results every time.
FAQ
1. What Are Phospho-Specific Antibodies?
Phospho-specific antibodies are made to detect proteins only when they have a phosphate group linked to a specific amino acid residue. This empowers scientists understand if a protein is "turned on" or active, based on its phosphorylation state.
2. How to Detect Phosphorylated Proteins in a Western Blot?
To find out if a protein is phosphorylated using Western blot:
Use a phospho-specific antibody that binds only to the phosphorylated form of the protein.
You can also use a “regular” antibody for the same amino acid sequence of the protein that the phospho-specific antibody is binding to (but in this case, this antibody will not bind if there is a phosphate group present) in order to compare how much of it is phosphorylated versus how much is non-phosphorylated (or “total” protein, if the “normal” antibody’s epitopes are non-phospho-site-specific).
3. How to Choose the Best Antibody?
Here are some simple tips to help you pick the right antibody:
Know your target
Match your sample characteristics
Confirm the intended use is appropriate
Check “host” and “type”
Check the “quality” of the presented data/images
Appraise whether the available validation meets your needs
Submit a Question
Please complete the form below and a representative will contact you as soon as possible.
Request more Information
Please complete the form below and a representative will contact you as soon as possible.
Request a Manual
Please complete the form below and a representative will contact you as soon as possible.
Request a Quote
Please complete the form below and a representative will contact you as soon as possible.